UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~October~~November, 2025

Commission File Number 000-29962

Kazia Therapeutics Limited

(Translation of registrant’s name into English)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

OnAs ~~October~~previously 7disclosed, ~~2025,~~ Kazia Therapeutics Limited (the “Company”) orreceived a notice (the “~~Kazia~~Notice”) ~~announced~~from ~~an exclusive~~the ~~collaboration~~Listing ~~and~~Qualifications ~~in-licensing~~department ~~agreement~~(the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on May 12, 2025 notifying the Company that from March 28, 2025 to May 9, 2025, the Company’s Market Value of Listed Securities (“~~Agreement~~MVLS”) ~~with~~was ~~QIMR~~below ~~Berghofer~~the minimum of $35 million required for acontinued ~~first-in-class~~listing ~~PD-L1~~on ~~degrader~~The ~~program~~Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). ~~The~~In ~~lead~~accordance ~~optimized~~with ~~compound,~~Nasdaq Listing ~~NDL2~~Rule 5810(c)(3)(C), isNasdaq anprovided ~~advanced~~the ~~PD-L1~~Company ~~protein~~with ~~degrader~~180 ~~currently~~calendar indays, ~~development~~or ~~and~~until ~~represents~~November 10, a2025 ~~new~~(the ~~and~~“Compliance ~~innovative~~Date”), ~~frontier~~to ~~of cancer~~regain ~~immunotherapy~~compliance with the MVLS Requirement.

~~The~~On ~~program~~November 12, ~~will~~2025, ~~initially~~the ~~target~~Company ~~advanced~~received ~~breast~~a ~~cancer~~staff ~~and~~determination ~~non-small~~letter ~~cell~~(“Staff Letter”) from the Staff of Nasdaq indicating ~~lung~~that ~~cancer~~the ~~(NSCLC),~~Company ~~where~~had ~~PD-1/PD-L1~~not ~~immunotherapies~~regained ~~are~~compliance ~~widely~~with ~~used~~the ~~but~~MVLS ~~resistance~~Requirement ~~remains~~by ~~common~~November 10, 2025. ~~IND-enabling~~Pursuant ~~studies~~to ~~are expected~~the toNasdaq ~~commence~~Listing ~~within~~Rules ~~six~~and ~~months~~the Staff Letter, ~~with~~unless the Company timely requests a ~~goal~~hearing ofbefore ~~initiating~~a ~~first-in-human~~Hearings ~~studies~~Panel ~~within~~(the “Panel”), ~~approximately~~the 15Company’s ~~months.~~securities ~~Kazia~~would ~~also~~be ~~intends~~subject to ~~explore~~suspension/delisting. ~~synergistic opportunities~~Accordingly, the Company intends to ~~combine~~timely ~~NDL2~~request ~~with~~a ~~its~~hearing ~~existing~~before ~~pipeline~~the ~~assets,~~Panel. ~~including~~The ~~paxalisib~~hearing (arequest ~~pan-PI3K/mTOR~~will ~~inhibitor)~~automatically ~~and~~stay ~~EVT801~~any (asuspension ~~selective~~or ~~VEGFR3~~delisting action ~~inhibitor),~~pending ~~given~~the ~~their~~hearing ~~complementary~~and ~~mechanisms~~the expiration of ~~action~~any ~~in modulating~~additional extension period granted by the ~~tumor~~Panel ~~microenvironment~~following the hearing.

~~Under~~At the hearing, ~~terms~~the ofCompany ~~the~~intends ~~Agreement,~~to ~~Kazia~~demonstrate ~~will~~its ~~make~~ability ~~a one-time~~to ~~payment~~regain ofcompliance ~~approximately~~with ~~$1.39 million~~the 15deficiencies ~~business~~cited ~~days~~by ~~after~~the ~~signing~~Staff, isas ~~responsible~~well ~~for~~as its ability to sustain long-term compliance with all ~~development~~applicable ~~costs~~maintenance criteria. ~~Kazia~~ ~~will~~There ~~receive~~can abe ~~percentage~~no ofassurance ~~commercialization~~that the ~~revenue~~Company’s ~~ranging~~plan ~~from mid-~~to~~-high~~ ~~double~~regain ~~digits~~compliance ~~depending~~presented onat the ~~stage~~hearing ofwill ~~development~~be accepted by the Panel, ~~which~~or ~~includes~~that, ~~any~~if ~~out-licensing~~it ~~payments~~is, ~~received~~the ~~from~~Company ~~third~~will ~~parties~~be able to regain compliance with the applicable Nasdaq listing requirements.

OnThe ~~October~~Company 7,hereby ~~2025,~~incorporates ~~Kazia~~by ~~issued~~reference athe ~~press~~information ~~release~~contained ~~titled~~herein ~~“Kazia~~into ~~Therapeutics~~the ~~Announces~~Company’s ~~Collaboration~~registration ~~and~~statement ~~In-Licensing~~on ~~Agreement~~Form ~~for First~~F-~~in-Class~~3 ~~PD-L1~~(File ~~Protein Degrader Program~~No.~~” A copy of this release is attached hereto as Exhibit 99~~ 333-281937).1 ~~and is incorporated herein by reference.~~

The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend, Chief Executive Officer of the Company, and the quote of Professor Sudha Rao, Principal Investigator at QIMR Berghofer, contained in Exhibit 99.1, into the Company’s registration statement on Form F-3 (File No. 333-281937).

Forward-Looking Statements

This ~~announcement~~ report of foreign private issuer on Form 6-K may contain forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” or other similar words. Any statement describing Kazia’s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, statements regarding: Kazia’s ~~the~~intent ~~potential~~to ~~benefits~~demonstrate ofits ~~NDL2~~ability ~~and~~to ~~the~~regain ~~plans~~compliance ~~and~~with ~~goals~~the ofMVLS ~~developing NDL2 formulation~~requirement, the ~~anticipated~~outcome ~~development~~of ~~pathways~~the ~~and~~Panet’s ~~combinations~~review of ~~NDL2,~~any ~~the~~Kazia ~~anticipated~~appeal ~~payments~~of ~~under~~ the ~~Agreement,~~ ~~the timing for results and data related to Kazia~~Staff’s ~~clinical and preclinical trials~~determination, ~~Kazia’s strategy~~ and ~~plans~~any ~~with~~course ~~respect to its paxalisib program, the potential benefits~~ of ~~paxalisib~~action asto anregain ~~investigational~~compliance ~~PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions~~ with ~~regulatory agencies and~~ the Nasdaq ~~potential~~continued ~~market~~listing ~~opportunity for paxalisib~~requirements. Such statements are based on Kazia’s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with ~~clinical~~ and preclinical trials and product development, including the risk that interim or early data may not be consistent with final data, risks related to regulatory approvals, risks related to the impact of global economic conditions, and risks related to Kazia’s ability to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia’s Annual Report, filed on ~~Form~~ Form 20-F with the SEC on November 7, 2025, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this ~~announcement~~report of foreign private issuer on Form 6-K.

EXHIBIT LIST

Exhibit		Description
99.1		Press Release of Kazia Therapeutics Limited dated October 7, 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Kazia Therapeutics Limited (Registrant) ~~/s/ John Friend John Friend Chief Executive Officer Date: October 7, 2025~~

/s/ John Friend

John Friend

Chief Executive Officer

Date: November 18, 2025

Filing Compare · KAZIA THERAPEUTICS LTD